Last reviewed · How we verify

Stevens-Johnson syndrome — Treatment Landscape & Competitive Intelligence

Stevens-Johnson syndrome (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Stevens-Johnson syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Acthar Gel CORTICOTROPIN Mallinckrodt Ireland Adrenocorticotropic Hormone [EPC] Melanocyte-stimulating hormone receptor 1950-01-01
prednisolon prednisolon Hannover Medical School Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Schering) · 1 drug in Stevens-Johnson syndrome
  2. Hannover Medical School · 1 drug in Stevens-Johnson syndrome
  3. Mallinckrodt Ireland · 1 drug in Stevens-Johnson syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Stevens-Johnson syndrome:

Cite this brief

Drug Landscape (2026). Stevens-Johnson syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/stevens-johnson-syndrome. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing